Sucampo Pharmaceuticals, Inc. (SCMP)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.96-0.05 (-0.45%)
At close: 4:00 PM EDT
People also watch:
SUPNRPTPDEPOCEMPHZNP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open11.00
Prev Close11.01
Bid7.14 x 100
Ask11.15 x 1000
Day's Range10.85 - 11.05
52wk Range9.59 - 29.67
1y Target EstN/A
Market Cap469.2M
P/E Ratio (ttm)38.46
Beta1.10
Volume221,423
Avg Vol (3m)385,778
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : August 22, 2016
    Capital Cube10 days ago

    Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : August 22, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sucampo Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Capital Cube17 days ago

    ETF’s with exposure to Sucampo Pharmaceuticals, Inc. : August 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Sucampo Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to SCMP-US. Comparing the performance and risk of Sucampo Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
    Capital Cube22 days ago

    Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016

    Categories: Yahoo Finance Click here to see latest analysis Sucampo Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Sucampo Pharmaceuticals, Inc. – Nektar Therapeutics, Progenics Pharmaceuticals, Inc., Pfizer Inc., Akorn, Inc., Ironwood Pharmaceuticals, Inc. Class A and Abbott Laboratories (NKTR-US, PGNX-US, PFE-US, AKRX-US, IRWD-US ... Read more (Read more...)